Form 10-Q Celator Pharmaceuticals For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Celator Pharmaceuticals (CPXX) Posts Q3 Loss of 21c/Share
November 14, 2014 7:39 AM ESTCelator Pharmaceuticals (NASDAQ: CPXX) reported Q3 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25).
Third Quarter 2014 and Recent Business Highlights:
CPX-351:
In October, Celator announced it had achieved its target enrollment in a Phase 3 clinical study of CPX-351 Liposome for Injection in patients with high-risk (secondary) acute myeloid leukemia (AML).In September, Celator announced the publication of preclinical data in Pediatric Blood & Cancer that further characterize the therapeutic potential of CPX-351 and support its ongoing clinical testing in pediatric patients with acute lymphoblastic leukemia... More